Monday, October 25, 2010: 3:00 PM
Sheraton Hall E/F (Sheraton Centre Toronto Hotel)
* Candidate for the Lee B. Lusted Student Prize Competition
Click here to view Poster Number Acronyms
Poster Board / Category
3
QMA
ESTIMATING SURIVAL GAINS – CAN WE RELY ON “END-OF-STUDY” RESULTS?
Ivar Sønbø Kristiansen, MD, PhD, MPH, University of Oslo, Oslo, Norway and Henrik Stovring, PhD, University of Arhus, Arhus, Denmark
4
HSP
COMPARISON OF THREE INDIRECT MEASURES OF HEALTH UTILITIES IN HIV
Pierre K. Isogai1, Nicole Mittmann1, Sergio Rueda2, Anita R. Rachlis1, Ahmed M. Bayoumi, MD, MSc3, Ron Rosenes2, Nancy Risebrough4 and Sean B. Rourke2, (1)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (2)Ontario HIV Treatment Network, Toronto, ON, Canada, (3)Centre for Research on Inner City Health, the Keenan Research Centre in the Li Ka Shing Knowledge Institute, Toronto, ON, Canada, (4)Oxford Outcomes, Toronto, ON, Canada
5
HSP
MODEL TO PREDICT HEALTH UTILITY SCORES FROM CD4 COUNT IN HIV
Nicole Mittmann1, Pierre K. Isogai1, Sergio Rueda2, Anita R. Rachlis1, Ahmed M. Bayoumi, MD, MSc3, Ron Rosenes2, Nancy Risebrough4 and Sean B. Rourke2, (1)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (2)Ontario HIV Treatment Network, Toronto, ON, Canada, (3)Centre for Research on Inner City Health, the Keenan Research Centre in the Li Ka Shing Knowledge Institute, Toronto, ON, Canada, (4)Oxford Outcomes, Toronto, ON, Canada
8
QMA
MICROSIMULATION METHODS AND THEIR APPLICABILITY IN THE EVALUATION OF PERSONALIZED MEDICINE STRATEGIES
Beate Jahn, PhD1, Ursula Rochau, MD1, Nikolai Mühlberger, DVM, MPH1, Gaby Sroczynski, PhD, MPH1, Annette Conrads-Frank, PhD2 and Uwe Siebert, MD, MPH, MSc, SD1, (1)UMIT - University for Health Sciences, ONCOTYROL - Center for Personalized Cancer Medicine, Hall, Austria, (2)UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
9
HTA
COST-EFFECTIVENESS ANALYSIS OF CAST VERSUS SPLINT IN CHILDREN WITH ACCEPTABLY ANGULATED WRIST FRACTURES
Camill von Keyserlingk, MA1, Kathy Boutis, BSc, MSc, MD, FRCPC2, Andrew R. Willan, PhD3, Robert Hopkins, MA4 and Ron Goeree, MA4, (1)McMaster University / St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, (2)Hospital for Sick Children, Toronto, ON, Canada, (3)SickKids Research Institute, Toronto, ON, Canada, (4)McMaster University, Hamilton, ON, Canada
10
HTA
COST EFFECTIVENESS OF ANTENATAL STEROIDS IN LATE PRETERM PREGNANCIES
Anjali Kaimal, MD, MAS1, Sarah Little, MD1, Brian Shaffer, MD2, Yvonne Cheng, MD, MPH2, Marya Zlatnik, MD, MMS2 and Aaron B. Caughey, MD, MPP, MPH, PhD2, (1)Massachusetts General Hospital, Harvard Medical School, Boston, MA, (2)University of California, San Francisco, CA
11
HTA
MODELING PERFORMANCE OF IMAGING : A NEW PROPOSITION FOR PERFORMANCE APPRAISAL
Valerie G. Buthion, PhD, University of Lyon, Lyon, France, Vincent Augusto Jr., PhD, École Nationale Supérieure des Mines de Saint-Étiennne, Saint Etienne, France, Michel Nonent Sr., MD, PhD, Centre Hospitalo-Universitaire de Brest, Brest, France and Philippe Douek Sr., MD, PhD, Hospices Civiles de lyon, Bron, France
12
HSR
COST-EFFECTIVENESS OF GENE EXPRESSION PROFILING IN EARLY BREAST CANCER
Nathalie A. Kulin, MSc1, Deborah Marshall, PhD1, Elisabeth A.L. Fenwick, PhD2, Elena B. Elkin, PhD3, Mike Hassett4, Ilia Ferrusi, BSc5 and Kathryn Phillips6, (1)University of Calgary, Calgary, AB, Canada, (2)University of Glasgow, Glasgow, United Kingdom, (3)Memorial Sloan-Kettering Cancer Center, New York, NY, (4)Harvard Medical School, Boston, MA, (5)Centre for Evaluation of Medicines, Hamilton, ON, Canada, (6)Univeristy of California San Francisco, San Francisco, CA
13
HSR
COST EFFECTIVENESS OF EARLIER CATARACT SURGERY TO PREVENT MOTOR VEHICLE COLLISIONS
Stephen T. Mennemeyer, Ph.D.1, Cynthia Owsley, Ph.D.2, Gerald McGwin, Ph.D.1 and Susan Vogt, M.S.3, (1)University of Alabama at Birmingham School of Public Health, Birmingham, AL, (2)University of Alabam at Birmingham, Birmingham, AL, (3)University of Alabama at Birmingham, Birmingham, AL
14
HSR
THE COST-EFFECTIVENESS OF PALIVIZUMAB: A SYSTEMATIC REVIEW OF THE EVIDENCE
Kelly A. Smart1, Bosco A. Paes, MB, BS, FRCPI, FRCPC2 and Krista L. Lanctôt, PhD1, (1)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (2)McMaster Children's Hospital, Hamilton, ON, Canada
15
HSR
*
THE COST-EFFECTIVENESS OF HIGH FIVE FOR KIDS: A PEDIATRIC PRIMARY CARE OBESITY PREVENTION PROGRAM
Davene R. Wright1, Elsie Taveras, MD, MPH2, Matthew Gillman, MD, SM2, Christine M. Horan, MPH3, Katherine H. Hohman, MPH4, Steven Gortmaker, PhD5 and Lisa Prosser, PhD6, (1)Harvard University, Boston, MA, (2)Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, (3)Harvard Pilgrim Health Care Institute, Boston, MA, (4)YMCA of the USA, Washington, DC, (5)Harvard School of Public Health, Boston, MA, (6)University of Michigan, Ann Arbor, MI
17
HSR
CURRENT STATUS AND SOCIETAL CONSENSUS REGARDING END-OF-LIFE TREATMENT DECISIONS IN KOREA
Dae Seog Heo, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, Jong-Myon Bae, MD, PhD, National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea and Ho-Geol Ryu, MD, PhD, Boramae Medical Center, Seoul National University, Seoul, South Korea
18
QMA
UNIFYING RESEARCH AND REIMBURSEMENT DECISIONS: A FRAMEWORK AND ALGORITHM FOR POLICY CHOICE
D. Eldon Spackman, PhD, Susan Griffin, MSc, BSc and Karl Claxton, PhD, MSc, BA, University of York, York, United Kingdom
19
QMA
THE VALUE OF EVIDENCE: A RE-ANALYSIS OF THE USE OF STEROIDS IN HEAD INJURY
Susan Griffin, MSc, BSc, Karl Claxton, PhD, MSc, BA and Claire McKenna, PhD, University of York, York, United Kingdom
20
HSR
COST-EFFECTIVE TREATMENT THRESHOLDS FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN
Kensuke Moriwaki, MS1, Hirotaka Komaba, MD, PhD2, Masafumi Fukagawa, MD, PhD2, Hiroki Inoue, MD, PhD1, Takeshi Toujo, MD, PhD1, Shinichi Noto, OTR, PhD1 and Hideaki E. Takahashi, MD, PhD1, (1)Niigata University of Health and Welfare, Niigata, Japan, (2)Tokai University School of Medicine, Kanagawa, Japan
21
HSR
THE IMPACT OF DEPRESSION ON MEDICATION ADHERENCE IN A CALIFORNIA MEDICAID POPULATION WITH CARDIOVASCULAR DISEASE
Joanne Wu, MD, MS1, Tara K. Knight, PhD1, Julie L. Priest, MSPH2, C. Ron Cantrell, Ph.D.2 and Michael B. Nichol, PhD1, (1)University of Southern California, Los Angeles, CA, (2)GlaxoSmithKline, Research Triangle Park, NC
23
HSR
THE IMPACT OF HEPATITIS C ON WORK PRODUCTIVITY AMONG AFRICAN-AMERICAN AND HIGH VIRAL LOAD PATIENTS
Jan-Samuel Wagner, BS, Kantar Health, Princeton, NJ, Marco DiBonaventura, PhD, Kantar Health, New York, NY, Yong Yuan, PhD, Bristol-Myers Squibb, Plainsboro, NJ, Gilbert L'Italien, Bristol-Myers Squibb, Princeton, NJ and Ray Kim, MD, Mayo Clinic, Rochesterd, MN
24
HSR
THE COST IMPLICATIONS OF SHARED DECISION MAKING USING DECISION AIDS: A META-ANALYSIS AND CRITICAL APPRAISAL OF THE LITERATURE
Moritz H. Hansen, MD1, Greg Goldstein2 and Nananda F. Col, MD, MPH, MPP2, (1)Maine MEdical Center, Portland, ME, (2)Maine Medical Center, Portland, ME
25
HSR
DECISION MAKERS' PERCEPTIONS OF DECISION MODELS: A CASE STUDY
Ava John-Baptiste, PhD1, Marilyn Schapira, MD, MPH2, James D. Chambers, MPharm, MSc3, Peter Neumann, ScD3, Joanna Siegel, RN, SM, SD1, Catherine Cravens, MPH1 and William F. Lawrence1, (1)Agency for Healthcare Research and Quality, Rockville, MD, (2)Medical College of Wisconsin, Milwaukee, WI, (3)The Center for the Evaluation of Value and Risk in Health, Boston, MA
28
HSP
COMMUNITY-BASED VALUES FOR H1N1 INFLUENZA ILLNESSES AND VACCINATION-RELATED ADVERSE EVENTS
Tara A. Lavelle, MS1, Achamyeleh Gebremariam, MS2, Kara Lamarand, MPH2 and Lisa Prosser, PhD2, (1)Harvard University, Cambridge, MA, (2)University of Michigan, Ann Arbor, MI
29
HSP
EFFECTS ON ILLNESS ON CAREGIVERS AND FAMILIES: A REVIEW OF SPILLOVER EFFECTS IN HEALTH
Eve Wittenberg, PhD1, Gail Strickler, PhD1 and Lisa Prosser, PhD2, (1)Brandeis University, Waltham, MA, (2)University of Michigan, Ann Arbor, MI
30
JDM
PATIENT'S SALIENT BELIEFS ABOUT COMMUNICATING AND MAKING DECISIONS WITH PHYSICIANS
France Legare, MD, PhD, CCFP, F1, Dominick Frosch, PhD2, Caroline Tietbohl, BA2, Suepattra May, PhD, MPH2 and Glyn Elwyn, MD, PhD3, (1)Laval University, Quebec, QC, Canada, (2)Palo Alto Medical Foundation Research Institute, Palo Alto, CA, (3)Cardiff University, Cardiff, United Kingdom
31
JDM
*
ARE SECOND-OPINIONS OBJECTIVE? BIASES IN SECOND-OPINION CONSULTATIONS
Geva Vashitz, MSc, Technion Institute of Technology, Haifa, Israel, Nadav Davidovitch, MD, PhD, Ben-Gurion University of the Negev, Be’er-Sheva, Israel and Joseph S. Pliskin, PhD, Ben-Gurion University of the Negev, Be'er-Sheva, Israel
32
JDM
DEVELOPMENT OF DECISION SUPPORT SYSTEM FOR SUBJECTS TESTED POSITIVE FOR CANCER
Michi Sakai, MPH1, Noriaki Aoki, MD2, Satoko Zenitani, MPH1, Sakurako Narita, MPH1, Yoshiko Kakihara, RN1, Fumio Takesue, MD3, Takuro Shimbo, MD4 and Sachiko Ohta, MD5, (1)Center for Health Service, Outcomes Research and Development-Japan (CHORD-J), Tokyo, Japan, (2)University of Texas - Houston, Houston, TX, (3)Nara Prefecture Government, Tokyo, Japan, (4)International Medical Center of Japan, Tokyo, Japan, (5)Health Informatics Management Professionals (HIMAP), Tokyo, Japan
33
JDM
PATIENT'S FACIAL APPEARANCE ALTERS LIKELIHOOD OF PROVIDING MEDICAL TREATMENT
Meredith E. Young, PhD1, Benedict Jones, PhD2, Katherine Holshausen, BSc.3 and David Feinberg, PhD3, (1)McGill University, Montreal, QC, Canada, (2)University of Aberdeen, Aberdeen, Scotland, (3)McMaster University, Hamilton, ON, Canada
34
JDM
EXPECTATIONS AND SATISFACTION AFTER ELECTIVE CERVICAL SPINE SURGERY FOR DEGENERATIVE CONDITIONS
Marjorie C. Wang, MD, MPH, Marilyn Schapira, MD, MPH and Ann B. Nattinger, MD, MPH, Medical College of Wisconsin, Milwaukee, WI
35
JDM
ONCOLOGISTS' ATTITUDES AND BELIEFS ABOUT PATIENT PARTICIPATION IN CANCER CLINICAL TRIALS
Margaret M. Byrne, PhD, Julie Kornfeld, MPH, Stefan Glück, MD, PhD, Judith Hurley, MD and Michael Antoni, University of Miami, Miami, FL
36
JDM
GOALS, SYMPTOMS, SIGNS, AND TREATMENTS AMONG WOMEN WITH PELVIC FLOOR DISORDERS
Jeffrey D. Johnson, BS1, Kevin F. Spratt, PhD2 and James L. Whiteside, MS, MD2, (1)Dartmouth Medical School, Lebanon, NH, (2)Dartmouth-Hitchcock Medical Center, Lebanon, NH
39
JDM
USING MIXED TREATMENT COMPARISONS TO GENERATE RECOMMENDATIONS FOR OPTIMAL USE OF MEDICATIONS
Sumeet R. Singh, BScPhm, MSc, RPh, Brendan McIntosh, BSc, MSc, Chris Cameron, BSc, EngDip, MSc and Denis Belanger, B.Sc.Phm., ACPR, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada
40
JDM
*
PERSONALIZED PREVENTION OF CORONARY ARTERY DISEASE
Bart S. Ferket, MD1, Bob J.H. van Kempen, MSc1, Jan Heeringa, MD, PhD1, Sandra Spronk, PhD1, Rogier L.G. Nijhuis, MD, PhD2, Ewout W. Steyerberg, PhD1 and M.G. Myriam Hunink, MD, PhD1, (1)Erasmus MC, Rotterdam, Netherlands, (2)ZGT Hengelo, Hengelo, Netherlands
41
JDM
STEREOTACTIC BODY RADIOTHERAPY VERSUS SURGERY FOR MEDICALLY OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: A MARKOV MODEL BASED DECISION ANALYSIS
Malek B. Hannouf, BSc1, Alexander V. Louie, BSc, MD2, George B. Rodrigues, MD, FRCPC, MSc2, David A. Palma, BSc, MD2, Jeffrey Q. Cao, MD2, Brian P. Yaremko, MSc, PEng, MD2, Richard Malthaner, MSc, MD2, Joseph D. Mocanu, PhD1 and Greg Zaric, Ph.D1, (1)University of Western Ontario, London, ON, Canada, (2)London Regional Cancer Program, London, ON, Canada
43
JDM
*
IS THERE A NEED FOR A PATIENT DECISION AID FOR PRENATAL SCREENING?: PRENATAL PATIENTS' REPORTS ABOUT THEIR DECISION PROCESS
Rebecca S. Uranga, MD, Susan Berg, MS, CGC, Devin Applebee, MS, CGC, Valerie Hani LaCroix, MSc, CGC and E. Rebecca Pschirrer, MD, MPH, Dartmouth Hitchcock Medical Center, Lebanon, NH
44
JDM
INTERRELATIONSHIPS AMONG SOCIAL SUPPORT, WORRY ABOUT CANCER WORSENING, AND HEALTH-RELATED QUALITY OF LIFE AMONG EARLY-STAGE BREAST CANCER PATIENTS
Erika A. Waters, PhD, MPH, Ying Liu, MD, PhD and Donna B. Jeffe, PhD, Washington University School of Medicine, Saint Louis, MO
45
JDM
EVALUATING AN H1N1 DECISION AID FOR FAMILIES
Margaret L. Lawson, MD, MSc, FRCP1, Jennifer Kryworuchko, PhD, (c)2, Anton Saarimaki, MCS3 and Joel Barnes, MSc1, (1)Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, (2)University of Ottawa, Ottawa, ON, Canada, (3)Ottawa Hospital Research Institute, Ottawa, ON, Canada
46
JDM
EXPLORING THE EXPERIENCE OF ACUTE IMMUNE THROMBOCYTOPENIC PURPURA THROUGH NARRATIVES OF CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA, THEIR PARENTS, AND HEALTH CARE PROFESSIONALS
Carolyn E. Beck, MD, MSc, FRCPC1, Katherine Boydell, PhD1, Vicky Breakey, MD, FRCPC1, Catherine S. Birken, MD, MSc, FRCPC1, Elaine Stasiulis, MA, PhD, (c)1, Victor S. Blanchette, MD, FRCPC1, Hilary A. Llewellyn-Thomas, PhD2 and Patricia C. Parkin, MD, FRCPC1, (1)The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, (2)Dartmouth Medical School, Lebanon, NH
47
JDM
ANTIPSYCHOTIC DECISION AID ACCEPTABILITY: FEEDBACK FROM CLIENTS, FAMILY MEMBERS, AND PHYSICIANS
Anh Thu Bui, MD, California Institute for Mental Health, Palm Springs, CA and Doug DelPaggio, PharmD, MPA, Alameda County Behavioral Health Care Services, Oakland, CA
49
HTA
WHEN THE DECISION IS WHAT TO DECIDE: LITERATURE OVERVIEWS FOR HTA SCOPING
Matthew D. Mitchell, PhD1, Kendal Williams, MD, MPH1, Gretchen Kuntz, MSW, MSLIS2 and Craig A. Umscheid, MD, MSCE1, (1)University of Pennsylvania Health System, Philadelphia, PA, (2)University of Pennsylvania, Philadelphia, PA
51
JDM
*
SIMULATION TRAINING AND DECISION SUPPORT FOR MEDICAL EDUCATION
Anam Waheed1, Joerg Brunstein, M.A., equivalent, Education2, Bakr Nour, MD, FACS3, Angela Brunstein, PhD2 and Julien Abi Nahed, PhD4, (1)Texas A & M University at Qatar, Doha, Qatar, (2)Carnegie Mellon University in Qatar, Doha, Qatar, (3)Weill Cornell Medical College in Qatar, Doha, Qatar, (4)Qatar Robotic Surgery Center, Doha, Qatar
53
QMA
EXTERNAL VALIDATION OF A MODEL OF GLAUCOMA PROGRESSION USING INDIVIDUAL LEVEL DATA
Steven M. Kymes, Ph.D.1, Dennis L. Lambert, Ph.D.1, Dustin L. Stwalley1, David C. Musch, Ph.D., M.P.H.2, Chris A. Johnson, Ph.D.3 and Mae O. Gordon, Ph.D.1, (1)Washington University School of Medicine, Saint Louis, MO, (2)University of Michigan School of Medicine, Ann Arbor, MI, (3)University of Iowa, Iowa City, IA
54
HSP
DEVELOPMENT OF A MULTIATTRIBUTE INSTRUMENT FOR ESTIMATING UTILITIES (PREFERENCE WEIGHTS) IN PEOPLE WITH GLAUCOMA FROM THE NATIONAL EYE INSTITUTE VISION FUNCTION QUESTIONNAIRE
Steven M. Kymes, Ph.D.1, Colleen M. Peters, M.A.1, Kathleen M. Beusterien, M.P.H2, Sameer V. Kotak, B., Pharm, M.S.3, Jessica Grinspan2, Dustin L. Stwalley1 and Andreas Pleil, PhD3, (1)Washington University School of Medicine, Saint Louis, MO, (2)Oxford Outcomes, Washington, DC, (3)Pfizer, Inc., New York, NY
55
GLH
*
HEALTH INSURANCE, CATASTROPHIC MEDICAL SPENDING, AND DIABETES TREATMENT IN DEVELOPING COUNTRIES
Crystal M. Smith-Spangler, MD, Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, CA and Jeremy D. Goldhaber-Fiebert, PhD, Stanford University, Stanford, CA
56
QMA
*
IS THERE A DIFFERENCE BETWEEN ORGANICALLY AND CONVENTIONALLY GROWN PRODUCE? A SYSTEMATIC REVIEW OF THE HEALTH BENEFITS AND HARMS
Crystal M. Smith-Spangler, MD1, Vandana Sundaram, MPH1, James C. Bavinger, BA2, Maren Pearson2, Paul Eschbach2, Margaret L. Brandeau, PhD2 and Dena M. Bravata, MD, MS2, (1)Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, CA, (2)Stanford University, Stanford, CA
59
QMA
*
SET-VALUED DYNAMIC TREATMENT REGIMES
Eric B. Laber, MSc1, Mahdi Fard, MS2, Joelle Pineau, PhD2 and Susan A. Murphy1, (1)University of Michigan, Ann Arbor, MI, (2)McGill, Montreal, QC, Canada
